Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018

  • ID: 4529331
  • Drug Pipelines
  • 529 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bioneer Corp
  • Galapagos NV
  • Johnson & Johnson
  • PharmaLundensis AB
  • Respiratorius AB
  • MORE
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights:

This latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 39, 24, 1, 88, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bioneer Corp
  • Galapagos NV
  • Johnson & Johnson
  • PharmaLundensis AB
  • Respiratorius AB
  • MORE
Introduction

Chronic Obstructive Pulmonary Disease (COPD) - Overview

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 9: Number of Products under Development by Universities/Institutes, H1 2018

Table 10: Products under Development by Companies, H1 2018

Table 11: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 14: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 15: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 16: Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 17: Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 18: Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 19: Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 20: Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 21: Products under Development by Universities/Institutes, H1 2018

Table 22: Number of Products by Stage and Target, H1 2018

Table 23: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 24: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 25: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 26: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Table 27: Number of Products by Stage and Mechanism of Action, H1 2018

Table 28: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 29: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 30: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 31: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Table 32: Number of Products by Stage and Route of Administration, H1 2018

Table 33: Number of Products by Stage and Molecule Type, H1 2018

Table 34: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2018

Table 35: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018

Table 36: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals Inc, H1 2018

Table 37: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2018

Table 38: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018

Table 39: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2018

Table 40: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2018

Table 41: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2018

Table 42: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2018

Table 43: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp, H1 2018

Table 44: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H1 2018

Table 45: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arch Biopartners Inc, H1 2018

Table 46: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2018

Table 47: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H1 2018

Table 48: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2018

Table 49: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H1 2018

Table 50: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioblue Technologies Inc, H1 2018

Table 51: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H1 2018

Table 52: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Table 53: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2018

Table 54: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics Inc, H1 2018

Table 55: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Table 56: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H1 2018

Table 57: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2018

Table 58: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by China Resources Pharmaceutical Group Ltd, H1 2018

Table 59: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cipla Ltd, H1 2018

Table 60: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2018

Table 61: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H1 2018

Table 62: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H1 2018

Table 63: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Table 64: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Table 65: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2018

Table 66: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H1 2018

Table 67: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H1 2018

Table 68: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H1 2018

Table 69: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Evaxion Biotech ApS, H1 2018

Table 70: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2018

Table 71: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H1 2018

Table 72: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2018

Table 73: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

List of Figures

Figure 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Ache Laboratorios Farmaceuticos SA
  • Achillion Pharmaceuticals Inc
  • Adamis Pharmaceuticals Corp
  • Advanced Inhalation Therapies (AIT) Ltd
  • AlgiPharma AS
  • Allinaire Therapeutics LLC
  • Allinky Biopharma
  • Angiocrine Bioscience Inc
  • Angion Biomedica Corp
  • apceth Biopharma GmbH
  • Arch Biopartners Inc
  • Aridis Pharmaceuticals LLC
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bioblue Technologies Inc
  • Bioneer Corp
  • Boehringer Ingelheim GmbH
  • C4X Discovery Holdings PLC
  • Carolus Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Chiesi Farmaceutici SpA
  • China Resources Pharmaceutical Group Ltd
  • Cipla Ltd
  • Circassia Pharmaceuticals Plc
  • CSL Ltd
  • Cytokinetics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Diffusion Pharmaceuticals Inc
  • Domainex Ltd
  • Enterprise Therapeutics Ltd
  • Errant Gene Therapeutics LLC
  • Evaxion Biotech ApS
  • Galapagos NV
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Grifols SA
  • Hanmi Pharmaceuticals Co Ltd
  • Humanigen Inc
  • iCeutica Inc
  • Icure Pharmaceutical Inc
  • InMed Pharmaceuticals Inc
  • Insmed Inc
  • Intech Biopharm Ltd
  • Invion Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Johnson & Johnson
  • Kissei Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • MedImmune LLC
  • Mereo Biopharma Group Plc
  • Meridigen Biotech Co Ltd
  • Novartis AG
  • Octapharma AG
  • OncBioMune Pharmaceuticals Inc
  • OPKO Health Inc
  • Orchid Pharma Ltd
  • Orion Corporation
  • Pfizer Inc
  • PharmaLundensis AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Proteostasis Therapeutics Inc
  • Pulmagen Therapeutics LLP
  • Pulmatrix Inc
  • Pulmotect Inc
  • Qu Biologics Inc
  • Quark Pharmaceuticals Inc
  • Re-Pharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Resolys Bio Inc
  • Respira Therapeutics Inc
  • Respiratorius AB
  • rEVO Biologics Inc
  • Rhizen Pharmaceuticals SA
  • SATT North SAS
  • SolAeroMed Inc
  • sterna biologicals Gmbh & Co KG
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Synairgen Plc
  • Synovo GmbH
  • Syntrix Biosystems Inc
  • Teva Pharmaceutical Industries Ltd
  • Therabron Therapeutics Inc
  • Theravance Biopharma Inc
  • Torrent Pharmaceuticals Ltd
  • Unity Biotechnology Inc
  • Unizyme Laboratories A/S
  • Verona Pharma Plc
  • Yuhan Corp
  • Yungjin Pharm Co Ltd
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll